Prosecution Insights
Prosecution Insights
Technology area: Medical Devices & Mechanical Engineering
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Alpha Tau Medical Ltd. manages a patent portfolio in the Medical Devices & Mechanical Engineering technology area. The portfolio currently features 3 pending office actions, which are distributed among 3 distinct examiners. This distribution means that each pending matter is being evaluated by a different examiner, providing a variety of perspectives on the company's patent applications. This can help the applicant identify themes or unique challenges across their filings.
Despite the involvement of multiple examiners, the prosecution is concentrated within 1 distinct art unit. This suggests that the pending office actions are all related to a specific technical domain within medical devices. BAEK, JONGHWAN NMN is the busiest examiner for the portfolio, with 1 busiest examiner pending action. Since the total of 3 pending office actions is split evenly among the examiners, no single individual controls the majority of the portfolio's current trajectory. Practitioners must navigate the specific standards of one art unit while managing three separate examiner relationships.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, JONGHWAN NMN | 1 | 60.0% | +0.0% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| DIETZ, NOE ROBERT | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18113097 | Convection-Enhanced Diffusing Alpha-Emitter Radiation Therapy | DIETZ, NOE ROBERT | 21d |
| 18569650 | Intratumoral Alpha-Emitter Radiation in Combination with Immune Checkpoint Regulators | DONOHUE, SEAN R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569650 | Intratumoral Alpha-Emitter Radiation in Combination with Immune Checkpoint Regulators | DONOHUE, SEAN R | — |
| Art Unit | Apps |
|---|---|
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18412655 | Gel Loaded with Alpha-Emitter Radionuclides | BAEK, JONGHWAN NMN | — | §103§112DP | Non-Final OA | — | Pending | Jan 15, 2024 |
| 18569650 | Intratumoral Alpha-Emitter Radiation in Combination with Immune Checkpoint Regulators | DONOHUE, SEAN R | — | §102§103§112Other | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18113097 | Convection-Enhanced Diffusing Alpha-Emitter Radiation Therapy | DIETZ, NOE ROBERT | 3791 | §102§103 | Final Rejection | 21d | Pending | Feb 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial